A systematic review and meta-analysis on glymphatic flow dysfunction in depression:Evidence from the DTI-ALPS index.

J Affect DisordMay 14, 2026 (epub)
Clinical ResearchPsychiatryNeurology

Fuzhe Zhang, Qingyun Li, Mingyu Wang et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review and meta-analysis examined glymphatic flow dysfunction in Major Depressive Disorder (MDD) using the DTI-ALPS index. Analyzing data from 11 studies with 1470 MDD patients and 962 healthy controls, the study found a significant reduction in the DTI-ALPS index in MDD patients (SMD = -0.765, p < 0.001), indicating moderate glymphatic impairment correlated with symptom severity.

Key findings

  • MDD patients showed a significant reduction in the DTI-ALPS index (SMD = -0.765, p < 0.001).
  • Glymphatic dysfunction correlated with symptom severity (β = -0.2429, p < 0.05).
  • Age and disease duration were significant moderators of the effect size (p < 0.05).
  • No significant publication bias was detected (p < 0.05).

Why it matters

Understanding glymphatic dysfunction in MDD may provide insights into its pathophysiology and highlight potential neurobiological markers, which could inform future therapeutic strategies and interventions.

Source

PubMed · PMID 42140323

Published in J Affect Disord. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Psychiatry

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.